We are live on ! Find out more
NVNO

enVVeno Medical
NVNO

23 hedge funds and large institutions have $5.9M invested in enVVeno Medical in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more call options, than puts

Call options by funds: $16K | Put options by funds: $4K

28% more funds holding

Funds holding: 18 → 23 (+5)

0.03% more ownership

Funds ownership: 0.55% → 0.58% (+0.03%)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

31% less capital invested

Capital invested by funds: $8.5M → $5.9M (-$2.59M)

Holders
23
Holders Change
+5
Holders Change %
+27.78%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
4
Closed
–
Calls
$16K
Puts
$4K
Net Calls
+$12K
Net Calls Change
-$126K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$167K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$78.2K
3
TS
Tamar Securities
California
+$51.9K
4
Squarepoint
Squarepoint
New York
+$49.3K
5
Renaissance Technologies
Renaissance Technologies
New York
+$43.6K

Top Sellers

Rank Fund Capital Flow
1
AMCA
Arthur M. Cohen & Associates
Illinois
-$37.1K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$21.2K
3
UBS Group
UBS Group
Switzerland
-$10.5K
4
BlackRock
BlackRock
New York
-$2.73K

NVNO Hedge Fund Activity: Q2 2023 in Review

23 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical (NVNO) for Q2 2023, worth a combined $5.9M — down 31% from $8.5M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NVNO positions and 0 closed out — a net gain of 5 holders — while 4 added to existing stakes and 4 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $167K. The largest seller was Arthur M. Cohen & Associates, cutting an estimated $37.1K.

  • 23 institutional investors held enVVeno Medical (NVNO) as of Q2 2023, up from 18 in Q1 2023.
  • Funds reported $5.9M of enVVeno Medical stock for Q2 2023, down 31% quarter-over-quarter.
  • 5 funds opened new enVVeno Medical positions in Q2 2023 and 0 closed out, a net change of +5 holders.
  • The largest enVVeno Medical buyer in Q2 2023 was Citadel Advisors, an estimated $167K added.
  • The largest enVVeno Medical seller in Q2 2023 was Arthur M. Cohen & Associates, an estimated $37.1K sold.

Based on aggregated 13F filings for Q2 2023.